Publicaciones en colaboración con investigadores/as de University of Oxford (57)

2024

  1. Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study

    Alzheimer's and Dementia

  2. Blood-based multivariate methylation risk score for cognitive impairment and dementia

    Alzheimer's and Dementia

  3. CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease

    Alzheimer's and Dementia

  4. Extending the phenotypic spectrum assessed by the CDR plus NACC FTLD in genetic frontotemporal dementia

    Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 16, Núm. 2

  5. Impaired glymphatic system in genetic frontotemporal dementia: a GENFI study

    Brain Communications, Vol. 6, Núm. 4

  6. Involvement of the choroid plexus in Alzheimer’s disease pathophysiology: findings from mouse and human proteomic studies

    Fluids and Barriers of the CNS, Vol. 21, Núm. 1

  7. Long Non-Coding RNA Profile in Genetic Symptomatic and Presymptomatic Frontotemporal Dementia: A GENFI Study

    Journal of Alzheimer's Disease, Vol. 100, Núm. s1, pp. S187-S196

  8. Longitudinal cerebral perfusion in presymptomatic genetic frontotemporal dementia: GENFI results

    Alzheimer's and Dementia, Vol. 20, Núm. 5, pp. 3525-3542

2023

  1. Cerebellar and subcortical atrophy contribute to psychiatric symptoms in frontotemporal dementia

    Human Brain Mapping, Vol. 44, Núm. 7, pp. 2684-2700

  2. Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non-Alzheimer's disease pathophysiology

    Alzheimer's and Dementia, Vol. 19, Núm. 3, pp. 807-820

  3. Language impairment in the genetic forms of behavioural variant frontotemporal dementia

    Journal of Neurology, Vol. 270, Núm. 4, pp. 1976-1988

  4. Loss of brainstem white matter predicts onset and motor neuron symptoms in C9orf72 expansion carriers: a GENFI study

    Journal of Neurology, Vol. 270, Núm. 3, pp. 1573-1586

  5. Motor symptoms in genetic frontotemporal dementia: developing a new module for clinical rating scales

    Journal of Neurology, Vol. 270, Núm. 3, pp. 1466-1477

  6. Multivariate GWAS of Alzheimer’s disease CSF biomarker profiles implies GRIN2D in synaptic functioning

    Genome Medicine, Vol. 15, Núm. 1

  7. Network structure and transcriptomic vulnerability shape atrophy in frontotemporal dementia

    Brain, Vol. 146, Núm. 1, pp. 321-336

  8. Temporal dynamics predict symptom onset and cognitive decline in familial frontotemporal dementia

    Alzheimer's and Dementia, Vol. 19, Núm. 5, pp. 1947-1962

  9. Whole-exome rare-variant analysis of Alzheimer's disease and related biomarker traits

    Alzheimer's and Dementia, Vol. 19, Núm. 6, pp. 2317-2331

2022

  1. CSF glial markers are elevated in a subset of patients with genetic frontotemporal dementia

    Annals of Clinical and Translational Neurology, Vol. 9, Núm. 11, pp. 1764-1777

  2. Cognitive composites for genetic frontotemporal dementia: GENFI-Cog

    Alzheimer's Research and Therapy, Vol. 14, Núm. 1

  3. Data-driven staging of genetic frontotemporal dementia using multi-modal MRI

    Human Brain Mapping, Vol. 43, Núm. 6, pp. 1821-1835